366 related articles for article (PubMed ID: 9422570)
21. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
Stokes SH
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
[TBL] [Abstract][Full Text] [Related]
22. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
23. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
24. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy.
Zelefsky MJ; Aschkenasy E; Kelsen S; Leibel SA
Int J Radiat Oncol Biol Phys; 1997 Sep; 39(2):327-33. PubMed ID: 9308935
[TBL] [Abstract][Full Text] [Related]
25. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
[TBL] [Abstract][Full Text] [Related]
26. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer.
Fukunaga-Johnson N; Sandler HM; McLaughlin PW; Strawderman MS; Grijalva KH; Kish KE; Lichter AS
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):311-7. PubMed ID: 9226317
[TBL] [Abstract][Full Text] [Related]
27. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.
Cozzarini C; Montorsi F; Fiorino C; Alongi F; Bolognesi A; Da Pozzo LF; Guazzoni G; Freschi M; Roscigno M; Scattoni V; Rigatti P; Di Muzio N
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):966-74. PubMed ID: 19619960
[TBL] [Abstract][Full Text] [Related]
28. Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer.
Valicenti RK; Gomella LG; Ismail M; Mulholland SG; Petersen RO; Corn BW
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):501-6. PubMed ID: 9806507
[TBL] [Abstract][Full Text] [Related]
29. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
30. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?
Keyser D; Kupelian PA; Zippe CD; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):723-9. PubMed ID: 9240638
[TBL] [Abstract][Full Text] [Related]
31. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years.
Anscher MS; Clough R; Dodge R
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):369-75. PubMed ID: 10974449
[TBL] [Abstract][Full Text] [Related]
32. Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer.
Sasaki T; Nakamura K; Shioyama Y; Ohga S; Toba T; Urashima Y; Yoshitake T; Terashima H; Koga H; Naito S; Noma H; Komatsu K; Yamaguchi A; Hiratsuka Y; Hirano T; Hanada K; Abe M; Fujisawa Y; Honda H
Anticancer Res; 2006; 26(3B):2367-74. PubMed ID: 16821618
[TBL] [Abstract][Full Text] [Related]
33. Radiotherapy following radical prostatectomy in patients with adenocarcinoma of the prostate.
Petrovich Z; Lieskovsky G; Langholz B; Luxton G; Jozsef G; Skinner DG
Int J Radiat Oncol Biol Phys; 1991 Sep; 21(4):949-54. PubMed ID: 1917624
[TBL] [Abstract][Full Text] [Related]
34. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control.
Syndikus I; Pickles T; Kostashuk E; Sullivan LD
J Urol; 1996 Jun; 155(6):1983-6. PubMed ID: 8618303
[TBL] [Abstract][Full Text] [Related]
35. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP
Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198
[TBL] [Abstract][Full Text] [Related]
36. Implications of greater short-term PSA recurrence with laparoscopic as compared to retropubic radical prostatectomy for Japanese clinically localized prostate carcinomas.
Akita H; Okamura T; Ando R; Nagata D; Naruyama H; Yamada Y; Naiki T; Yasui T; Tozawa K; Kohri K
Asian Pac J Cancer Prev; 2011; 12(11):2959-61. PubMed ID: 22393971
[TBL] [Abstract][Full Text] [Related]
37. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
[TBL] [Abstract][Full Text] [Related]
38. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy.
Choo R; Hruby G; Hong J; Bahk E; Hong E; Danjoux C; Morton G; DeBoer G
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):269-76. PubMed ID: 12023129
[TBL] [Abstract][Full Text] [Related]
39. The effects of PSA kinetics on the outcome of hypofractionated salvage radiotherapy for biochemical recurrence of prostate cancer after prostatectomy.
Ishikawa H; Higuchi K; Kaminuma T; Takezawa Y; Saito Y; Etsunaga T; Maruo K; Kawamura H; Kubo N; Nakano T; Kobayashi M
J Radiat Res; 2020 Nov; 61(6):908-919. PubMed ID: 32888035
[TBL] [Abstract][Full Text] [Related]
40. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
